van Werkhoven, Erik
Hinsley, Samantha
Frangou, Eleni
Holmes, Jane
de Haan, Rosemarie
Hawkins, Maria
Brown, Sarah
Love, Sharon B http://orcid.org/0000-0002-6695-5390
Funding for this research was provided by:
Medical Research Council (MC_UU_12023/24)
Cancer Research UK (C49297/A27294, C1348/A25355)
Article History
Received: 1 October 2019
Accepted: 10 May 2020
First Online: 22 June 2020
Ethics approval and consent to participate
: The Chief Investigators for CHARIOT Professor Maria Hawkins (ExternalRef removed Identifier: NCT03641547) and the Olaparib and Chemoradiotherapy in Locally Advanced NSCLC trial Baukelien van Triest (ExternalRef removed Identifier: NCT01562210) gave permission for the design details to be discussed.
: Not applicable.
: RdH declares research grant funding from AstraZeneca to support 3 trials, including the NCT01562210 example used in this paper. All other authors declare that they have no competing interests.